6.7.8.5. platinum chemotherapy. cisplatin carboplatin monotherapy combinations shown limited activity unselected patients pre-docetaxel era . combination cabazitaxel carboplatin evaluated pre-treated mcrpc patients randomised phase i/ii trial. combination improved median pfs 4.5 months (95% ci: 3.5–5.7) 7.3 months (95% ci: 5.5–8.2; hr: 0.69, 95% ci: 0.50–0.95, p = 0.018) combination well tolerated . histopathological molecular level, preliminary evidence platinum adds efficacy patients aggressive variant pca molecular signatures including tp53, rb1, pten . patients mcrpc alterations ddr genes sensitive platinum chemotherapy unselected patients , also progression parp inhibitors. interestingly, contemporary retrospective series, unselected patients well patients without ddr gene alterations also showed 50% psa decline treated platinum 36% patients. view excellent tolerability e.g., carboplatin monotherapy, platinum could offered patients far advanced mcrpc harbouring ddr gene aberrations progressed standard treatment options. prospective controlled trials ongoing.